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BRIEF COMMUNICATION OPEN
Personalising adherence-enhancing interventions using a smart
inhaler in patients with COPD: an exploratory cost-
effectiveness analysis
Job F. M. van Boven 1,2, Breda Cushen 3, Imran Sulaiman3, Garrett Greene3, Elaine MacHale3, Matshediso C. Mokoka3,
Frank Doyle 4, Richard B. Reilly5, Kathleen Bennett6 and Richard W. Costello3,7
Four inhaler adherence clusters have been identiﬁed using the INCA audio device in COPD patients: (1) regular use/good technique,
(2) regular use/frequent technique errors, (3) irregular use/good technique, and (4) irregular use/frequent technique errors. Their
relationship with healthcare utilization and mortality was established, but the cost-effectiveness of adherence-enhancing
interventions is unknown. In this exploratory study, we aimed to estimate the potential cost-effectiveness of reaching optimal
adherence in the three suboptimal adherence clusters, i.e., a theoretical shift of clusters 2, 3, and 4 to cluster 1. Cost-effectiveness
was estimated over a 5-year time horizon using the Irish healthcare payer perspective. We used a previously developed COPD
health-economic model that was updated with INCA trial data and Irish national economic and epidemiological data. For each
cluster, interventions would result in additional quality-adjusted life years gained at reasonable investment. Cost-effectiveness was
most favorable in cluster 3, with possible cost savings of €845/annum/person.
npj Primary Care Respiratory Medicine  (2018) 28:24 ; doi:10.1038/s41533-018-0092-8
INTRODUCTION
In chronic obstructive pulmonary disease (COPD), real-world
adherence to maintenance therapy can be as low as 20%.1 In
contrast, trials report adherence rates of over 80% in most
participants.2 Previous studies showed that patients with high
adherence have signiﬁcantly better clinical and economic out-
comes.3 Consequently, interventions focusing on adherence
enhancement have shown to be effective and cost-effective.4,5
Yet, in these studies, only average adherence was assessed and no
distinction was made between the different aspects of non-
adherence. Optimal implementation of inhaled therapy involves
both regular use as well as good inhaler technique.6 In our
previous work, we identiﬁed four distinct clusters of inhaler
adherence that were associated with differential clinical out-
comes.7 Economic evaluations of adherence-enhancing interven-
tions in each of those clusters have not been performed, but could
help prioritizing speciﬁc target populations for tailored interven-
tions. The aim of this follow-up study is to estimate the potential
cost-effectiveness of reaching optimal adherence in each sub-
optimal adherence cluster.
RESULTS
The study’s baseline population characteristics (n= 226) have
been described elsewhere.1,7 In short, cluster 1 had the lowest
mortality during follow-up. Cluster 2 had the highest rate of
antibiotic and/or oral steroids community prescriptions. The
highest overall healthcare use was attributable to patients from
cluster 3. Cluster 4 had the highest mortality (Fig. 1).
Cost-effectiveness
Cost-effectiveness analysis results are shown in Table 1.
Adherence-enhancing interventions seem generally cost-effective,
given all ICERs are below the Irish cost-effectiveness threshold of
€45,000/QALY.8 In other words, this means that all adherence-
enhancing interventions would cost less than €45,000 to gain one
life-year in perfect health. For each cluster, the theoretical
intervention would result in additional life years and QALYs
gained. Notably, for cluster 3, an intervention would be cost-
saving (i.e., less costs and more QALYs).
DISCUSSION
We performed exploratory cost-effectiveness modeling to assess
the potential economic beneﬁts of improved adherence in three
clusters of patients with suboptimal adherence. In all clusters,
interventions seem cost-effective. Moreover, in patients with
irregular use but good inhaler technique, a possible cost-saving of
€845/annum/person could be yielded despite the higher cost of
medication arising from better adherence.
Remote monitoring of adherence on a longitudinal basis
provides an accurate evaluation of regularity of use as well as
inhaler technique. The use of a technology, such as the one
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described in this report, identiﬁed four patterns of adherence and
may give guidance as to how we might approach this challenge in
a personalized manner. Hence, in the future, by providing
personalized interventions to the highest risk groups we may
both improve adherence and have a positive impact on both
clinical and economic outcomes in those most in need, such as
those in cluster 3. The need for personalized adherence-
enhancing interventions has recently been highlighted.9 They
could include education and training on inhaler technique for
those with frequent technique errors, patient reminders for those
with irregular use due to forgetfulness, and shared decision-
making and motivational interviewing for those with irregular use
due to a conscious, intentional decision.9
This study is a ﬁrst attempt to estimate the cost-effectiveness of
interventions in different adherence clusters, but was limited by
the use of post hoc and short-term effectiveness data for the
different clusters. Regarding generalizability, absolute costs may
differ per country or setting, but we expect relative cluster results
to be comparable. Our exploratory cost-effectiveness model
estimates should be conﬁrmed when long-term clinical interven-
tion trial data become available, including extensive sensitivity
and scenario analyses as well as analyses in a non-admitted
primary care COPD population.
Fig. 1 Proportional contribution of each adherence cluster to all-cause clinical outcomes over the 12-month follow-up period (adjusted for
the number of participants per cluster). Reported differences are the absolute differences in the proportion of events attributable to cluster 3
vs. cluster 1 for emergency department and hospital admission and cluster 4 vs. cluster 1 for death. ^ denotes p= 0.05, *p < 0.05
Table 1. Cost-effectiveness of enhancing adherence based on a 5-year time horizon
Cluster Total costs Intervention costsa Medication costs Healthcare costs Life years QALYs
Cluster 2: Regular use, frequent technique errors
Intervention €11,386 €184 €2901 €8300 3.75 3.00
Cluster 2 €10,150 €0 €2723 €7428 3.52 2.81
Difference €1235 €184 €179 €872 0.23 0.19
ICER €6520/QALY gained
Cluster 3: Irregular use, good technique
Intervention €11,812 €184 €2936 €8692 3.80 3.03
Cluster 3 €12,657 €0 €2395 €10,262 3.40 2.70
Difference −€845 €184 €541 −€1570 0.39 0.33
ICER Cost-saving (i.e., less costs, more QALYs)
Cluster 4: Irregular use, frequent technique errors
Intervention €13,075 €184 €3000 €9891 3.88 3.10
Cluster 4 €10,180 €0 €1918 €8261 2.98 2.36
Difference €2896 €184 €1082 €1630 0.90 0.74
ICER €3935/QALY gained
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year
aNote that the mean per-patient intervention costs are slightly lower given some patients die within the ﬁrst year and so do not cost the full €200
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Personalized adherence interventions targeting patient-speciﬁc
regularity of inhaler use and inhaler technique could result in
clinical and economic beneﬁts for COPD patients.
METHODS
Study design
This was an exploratory cost-effectiveness analysis. Ethical approval for the
clinical study was obtained from the Beaumont Hospital Ethics Committee.
Patient population
Patient selection and data collection has been described previously.1
Brieﬂy, hospitalized patients with COPD, prescribed salmeterol/ﬂuticasone
propionate (Seretide®, GlaxoSmithKline, Ireland), were included and
written informed consent was obtained from all participants.
Inhaler adherence
Adherence was assessed using the INCATM device that can track both
timing and quality of inhaler use.1 The INCA acoustic recordings allowed
for identiﬁcation of the following four adherence clusters:7 (1) regular use/
good technique, (2) regular use/frequent technique errors, (3) irregular
use/good technique, and (4) irregular use/frequent technique errors.
Cluster-speciﬁc healthcare utilization and mortality was studied previously7
and is summarized in Fig. 1.
Cost-effectiveness analysis
The cost-effectiveness of enhanced adherence, i.e., the theoretical shift of
patients from poor adherence (i.e., cluster 2, 3, or 4) to good adherence
(i.e., cluster 1), was estimated. Therefore, a previously developed,
described, and validated health-economic model5 was used and populated
with Irish and INCA-speciﬁc cost (for medication, intervention, and
healthcare utilization) and effect (mortality and exacerbations) data
(Appendix 1). The model has received a high-quality score in the latest
COPD model review,10 and estimates the incremental cost-effectiveness
ratio (ICER) in terms of costs (2013, €) per quality-adjusted life-year (QALY)
gained from the Irish healthcare payer’s perspective assuming ﬁxed per-
patient intervention costs of €200 (authors’ estimation). Three ICERs were
calculated using cluster 1 as intervention and clusters 2, 3, and 4,
respectively, as usual care scenarios. In line with recommendations,11 a
policy-relevant time horizon of 5 years was used, taking into account a 5%
discount rate for both costs and effects as per Irish Health Information and
Quality Authority guidelines (www.hiqa.ie).
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